Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can conversation unlock clues to ALS speech decline?

NCT ID NCT06266403

Knowledge-focused Sponsor: Penn State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study investigates how engaging in structured conversations affects the speech of people with amyotrophic lateral sclerosis (ALS) compared to typical speakers. Participants will complete speaking tasks both alone and with a partner, allowing researchers to measure speech clarity, sound patterns, and conversational flow. The goal is to understand how social interaction influences communication in ALS, which could inform future therapeutic approaches.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Structured communicative interaction tasks
What this could lead to
If successful, this could inform communication strategies and interventions to help people with ALS maintain effective verbal interaction.
What could go wrong
This is an observational study, so it won't directly test a treatment. Results may not apply to all people with ALS, and the measures are exploratory.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Speakers with amyotrophic lateral sclerosis (ALS) (PALS-people with ALS) * diagnosis of ALS following the revised EL Escorial criteria * no history of other neurological conditions (e.g., stroke) * no cognitive impairment assessed by Telephone Montreal Cognitive Assessment (mini MoCA) * detectable speech disturbance according to the ALS Functional Rating Scale-Revised (ALSFRS-R) * the ability to produce single words * being a native speaker of American English (AE). Age-matched Speakers * passing the remote hearing screening * having no known speech, language, or neurological disorders per self-report * no cognitive impairment assessed by Telephone Montreal Cognitive Assessment (mini MoCA) * being a functionally native monolingual speaker of American English. Unfamiliar Interlocutors * passing the remote hearing screening * having no known speech, language or neurological disorders per self-report * being a native monolingual speaker of American English * having no experience communicating with people with dysarthria * being between the ages of 18 and 40. Exclusion Criteria: * None - if volunteer meets the inclusion criteria, then they will be enrolled

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyotrophic lateral sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Speech Core, Pennsylvania State University

    RECRUITING

    University Park, Pennsylvania, 16802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.